Health First Physical Therapy, Inc | |
2976 N Scatterfield Rd Ste 150, Anderson, IN 46012-1587 | |
(765) 643-8781 | |
Not Available |
Full Name | Health First Physical Therapy, Inc |
---|---|
Type | Facility |
Speciality | Pain Medicine - Interventional Pain Medicine |
Location | 2976 N Scatterfield Rd Ste 150, Anderson, Indiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1235395146 | NPI | - | NPPES |
200948260A | Medicaid | IN |
Mailing Address | Practice Location Address |
---|---|
Health First Physical Therapy, Inc 2976 N Scatterfield Rd, Suite 150, Anderson, IN 46012-1587 Ph: (765) 643-8781 | Health First Physical Therapy, Inc 2976 N Scatterfield Rd Ste 150, Anderson, IN 46012-1587 Ph: (765) 643-8781 |
News Archive
For years, pregnant women have been underrepresented in biomedical research. Current treatments, interventions and guidelines do a poor job of taking into consideration the diverse characteristics of all pregnant women.
Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.
Medicomp Systems newest documentation and patient management application, Quippe, has been imbedded into MED3OOO's InteGreat EHR. Quippe is an easy to use and learn interface that puts the power to care back into the hands of the clinicians and allows them to focus on the patient, not data entry.
A major new study has shown that rotavirus vaccination reduced infant diarrhoea deaths by 34% in rural Malawi, a region with high levels of child deaths.
Forest Laboratories, Inc. announced today that Teflaro(ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA).
› Verified 5 days ago